$SNDX
Syndax Pharmaceuticals Inc Stock $sndx

$sndx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000119312517336444 Filed on November 08, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$1.193M	$305.0K	$305.0K
YoY Change	291.15%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.080M	$3.560M	$3.270M
YoY Change	37.37%	8.87%	2.19%
% of Gross Profit
Research & Development	$16.60M	$12.19M	$12.27M
YoY Change	95.88%	-0.7%	313.54%
% of Gross Profit
Depreciation & Amortization	$150.0K	$150.0K
YoY Change	66.67%
% of Gross Profit
Operating Expenses	$20.68M	$15.75M	$15.54M
YoY Change	80.69%	1.34%	152.2%
Operating Profit	-$19.49M	-$15.45M	-$15.24M
YoY Change	74.93%	1.37%	160.12%
Interest Expense	$460.0K	$411.0K	$268.0K
YoY Change	70.37%	53.36%	-217.03%
% of Operating Profit
Other Income/Expense, Net	$385.0K	$358.0K	$269.0K
YoY Change	18.1%	33.09%	-114.36%
Pretax Income	-$19.10M	-$15.09M	-$14.97M
YoY Change	76.52%	0.8%	93.66%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$19.10M	-$15.09M	-$14.97M
YoY Change	76.64%	0.79%	93.62%
Net Earnings / Revenue	-1601.34%	-4946.89%	-4907.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$796.5K	-$678.5K	-$836.3K
COMMON SHARES
Basic Shares Outstanding	24.39M shares	22.22M shares	17.78M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$131.3M	$121.5M	$116.0M
YoY Change	22.71%	4.74%	15.42%
Cash & Equivalents	$35.17M	$20.73M	$12.75M
Short-Term Investments	$96.10M	$100.8M	$103.2M
Other Short-Term Assets	$1.800M	$1.900M	$1.000M
YoY Change	50.0%	90.0%	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$133.4M	$124.0M	$117.3M
YoY Change	22.98%	5.72%	15.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$267.0K	$286.0K	$283.0K
YoY Change	2.69%	1.06%	183.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.200M
YoY Change
Other Assets	$231.0K	$236.0K	$179.0K
YoY Change	-4.94%	31.84%	-88.07%
Total Long-Term Assets	$3.744M	$522.0K	$462.0K
YoY Change	644.33%	12.99%	-69.2%
TOTAL ASSETS
Total Short-Term Assets	$133.4M	$124.0M	$117.3M
Total Long-Term Assets	$3.744M	$522.0K	$462.0K
Total Assets	$137.2M	$124.5M	$117.7M
YoY Change	25.84%	5.75%	14.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.232M	$2.246M	$2.010M
YoY Change	-6.02%	11.74%	67.5%
Accrued Expenses	$12.00M	$10.70M	$5.900M
YoY Change	76.47%	81.36%	118.52%
Deferred Revenue	$1.573M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.80M	$14.21M	$9.147M
YoY Change	52.4%	55.32%	-32.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$310.0K	$267.0K	$223.0K
YoY Change	7.64%	19.73%	-98.8%
Total Long-Term Liabilities	$17.07M	$13.57M	$14.75M
YoY Change	17.65%	-7.97%	-20.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.80M	$14.21M	$9.147M
Total Long-Term Liabilities	$17.07M	$13.57M	$14.75M
Total Liabilities	$32.87M	$27.78M	$23.90M
YoY Change	32.13%	16.25%	-25.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$366.1M	-$347.0M	-$294.5M
YoY Change	19.92%	17.84%
Common Stock	$470.6M	$443.7M	$388.2M
YoY Change	20.85%	14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$104.3M	$96.71M	$93.83M
YoY Change
Total Liabilities & Shareholders Equity	$137.2M	$124.5M	$117.7M
YoY Change	25.84%	5.75%	14.52%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$19.10M	-$15.09M	-$14.97M
YoY Change	76.64%	0.79%	93.62%
Depreciation, Depletion And Amortization	$150.0K	$150.0K
YoY Change	66.67%
Cash From Operating Activities	-$12.72M	-$10.18M	-$11.45M
YoY Change	22.07%	-11.09%	121.04%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$40.00K	-$50.00K
YoY Change		-20.0%	400.0%
Acquisitions
YoY Change
Other Investing Activities	$1.590M	$6.960M	$8.110M
YoY Change	-92.55%	-14.18%	-209.59%
Cash From Investing Activities	$1.550M	$6.920M	$8.050M
YoY Change	-92.73%	-14.04%	-208.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$24.90M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	25.61M	1.010M	1.710M
YoY Change	14964.71%	-40.94%	-97.15%
NET CHANGE
Cash From Operating Activities	-12.72M	-10.18M	-11.45M
Cash From Investing Activities	1.550M	6.920M	8.050M
Cash From Financing Activities	25.61M	1.010M	1.710M
Net Change In Cash	14.44M	-2.250M	-1.690M
YoY Change	30.32%	33.14%	-103.56%
FREE CASH FLOW
Cash From Operating Activities	-$12.72M	-$10.18M	-$11.45M
Capital Expenditures	-$40.00K	-$40.00K	-$50.00K
Free Cash Flow	-$12.68M	-$10.14M	-$11.40M
YoY Change	21.69%	-11.05%	120.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24389929	shares
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12753000
CY2016Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2017Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	10741000
CY2017Q3	us-gaap	Assets Current AssetsCurrent	123971000
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	354000
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	28000
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	443692000
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2246000
CY2017Q3	us-gaap	Assets Assets	124493000
CY2017Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	45000
CY2017Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000
CY2017Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	99834000
CY2017Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	99862000
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20732000
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22313001	shares
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	2000
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1220000
CY2017Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2017Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	893000
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	13305000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1220000
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1802000
CY2017Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	572000
CY2017Q3	us-gaap	Liabilities Liabilities	27779000
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124493000
CY2017Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13572000
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14207000
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	157000
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	236000
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	267000
CY2017Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	370000
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3277000
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Prepaid Insurance PrepaidInsurance	385000
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	286000
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-347008000
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	99862000
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	96714000
CY2017Q3	us-gaap	Supplies Supplies	316000
CY2017Q3	sndx	Reimbursable Costs ReimbursableCosts	741000
CY2017Q3	sndx	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	8428000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23179000
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6771000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	108510000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	247000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	56000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	389374000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2375000
CY2016Q4	us-gaap	Assets Assets	109013000
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	67000
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	81430000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	81486000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23844000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18215181	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2016Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1630000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	14220000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1641000
CY2016Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	306000
CY2016Q4	us-gaap	Liabilities Liabilities	24874000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109013000
CY2016Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14508000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10366000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	390000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	243000
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	288000
CY2016Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	202000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3029000
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Prepaid Insurance PrepaidInsurance	168000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	260000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	151000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-305293000
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	81486000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	84139000
CY2016Q4	us-gaap	Supplies Supplies	461000
CY2016Q4	sndx	Reimbursable Costs ReimbursableCosts	262000
CY2016Q4	sndx	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	4493000
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4170000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4170000
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	4665000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	42000
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3112000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41727000
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	233000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.08
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Entity Registrant Name EntityRegistrantName	SYNDAX PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001395937
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11777000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-915000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-206000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4008000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	248000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-51000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	959000
	us-gaap	Licenses Revenue LicensesRevenue	915000
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-28000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Nature of Business</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Syndax Pharmaceuticals, Inc. (the “Company”) is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications. The Company’s lead product candidate, entinostat, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. The U.S. Food and Drug Administration granted Breakthrough Therapy designation to entinostat when given in combination with exemestane following positive results from the Company’s ENCORE 301 Phase 2b clinical trial. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, the Company is evaluating entinostat as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for <font style="WHITE-SPACE: nowrap">non-small</font> cell lung cancer, melanoma and microsatellite stable colorectal cancer; with Genentech, Inc. for triple negative breast cancer; and with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. for ovarian cancer. The Company’s second product candidate, SNDX-6352, is a monoclonal antibody that targets the colony stimulating <font style="WHITE-SPACE: nowrap">factor-1</font> receptor to enhance the body’s immune response against tumors that have shown sensitivity to immunotherapy. The Company is evaluating SNDX-6352 in a multiple ascending dose Phase 1 clinical trial in cancer patients. The Company plans to continue to leverage the technical and business expertise of our management team and scientific collaborators to license, acquire and develop additional cancer therapies to expand our pipeline.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On October 13, 2017, the Company entered into a license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc (“Allergan”), under which Allergan granted to the Company a worldwide, sublicenseable, exclusive license to a portfolio of preclinical, orally-available, small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia (“MLL”) protein (the “Menin Assets”). Concurrent with the development of entinostat and SNDX-6352, the Company is also developing the Menin Assets to potentially treat MLL-r driven malignancies. The Company believes that the Menin Assets have the potential to be used to treat a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene (“MLL-r”). The Company expects to begin preclinical studies of the Menin Assets during the fourth quarter of 2017.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> On October 17, 2017, the Company entered into a purchase agreement with Biotech Value Fund, L.P. (“BVF”) and certain entities affiliated with BVF (the “Purchase Agreement”). Pursuant to the Purchase Agreement, the Company issued directly to BVF in a registered direct offering (the “Offering”), 2,021,018 shares of the Company’s common stock at a price of $12.37 per share, representing the closing price of the Company’s shares on the Nasdaq Global Select Market on Friday, October 13, 2017. The net proceeds from the Offering, after deducting estimated expenses, are expected to be approximately $24.8 million.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In March 2016, the Company completed its initial public offering (“IPO”) whereby it sold 4,809,475 shares of common stock at the initial public offering price of $12.00 per share, which included 409,475 shares issued pursuant to the underwriters’ partial exercise of their over-allotment option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were $50.5 million, net of underwriting discounts and commissions of $4.0 million and offering expenses of $3.1 million. Upon the closing of the IPO, all outstanding shares of the Company’s outstanding convertible preferred stock converted into 12,872,551 shares of common stock; and the Company’s outstanding warrant liability to purchase 357,840 shares of the Company’s common stock valued at $4.6 million was reclassified to additional <font style="WHITE-SPACE: nowrap">paid-in</font> capital. In connection with the closing of the Company’s IPO, the Company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, both of which were approved by the Company’s board of directors and stockholders on September 28, 2015 and February 24, 2016, respectively. Pursuant to the amended and restated certificate of incorporation, the Company is now authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In May 2017, the Company completed a <font style="WHITE-SPACE: nowrap">follow-on</font> public offering whereby the Company sold 3,950,190 shares of common stock at a price of $13.25 per share, which included 200,190 shares issued pursuant to the underwriters’ partial exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $48.7 million, net of underwriting discounts and commissions and estimated offering expenses payable by the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> In April 2017, the Company entered into a sales agreement with Cowen and Company, LLC (“Cowen”) under which the Company may issue and sell shares of our common stock having aggregate sales proceeds of up to $50.0 million from time to time through Cowen, acting as agent, in a series of one or more <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">at-the-market</font></font> (“ATM”) equity offerings. Cowen is not required to sell any specific amount, but acts as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. Shares sold pursuant to the sales agreement will be sold pursuant to a shelf registration statement, which became effective on April 20, 2017. Our common stock will be sold at prevailing market prices at the time of the sale; and as a result, prices may vary. We will pay Cowen up to 3% of the gross proceeds from any common stock sold through the sales agreement. During the three months ended September 30, 2017, the Company sold 92,511 shares of Common Stock pursuant to the ATM program, at an average price of $12.49 per share for gross proceeds of $1.2 million, resulting in net proceeds of $1.1 million after deducting sales commissions and offering expenses. As of September 30, 2017, $48.8 million of Common Stock remained available for sale under the ATM program.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks common to companies in the development stage, including, but not limited to, successful development of therapeutics, obtaining additional funding, protection of proprietary therapeutics, compliance with government regulations, fluctuations in operating results, dependence on key personnel and collaborative partners, and risks associated with industry changes. The Company’s long-term success is dependent upon its ability to successfully develop and market its product candidates, expand its oncology drug pipeline, earn revenue, obtain additional capital when needed, and ultimately, achieve profitable operations. The Company anticipates that it may be two or more years before any of our product candidates are approved, if ever, and the Company begins to generate revenue from sales of any of our product candidates. Accordingly, management expects to incur substantial losses on the ongoing development of our product candidates and does not expect to achieve positive cash flow from operations for the foreseeable future, if ever. As a result, the Company will continue to require additional capital to move forward with its business plan. While certain amounts of this additional capital were raised in the past, there can be no assurance that funds necessary beyond these amounts will be available in amounts or on terms sufficient to ensure ongoing operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company’s management believes that the cash, cash equivalents and short-term investments balances as of September 30, 2017 should enable the Company to maintain its planned operations for at least the next 12 months. The Company’s ability to fund all of its planned operations internally beyond that date, including the completion of its ongoing and planned clinical trial activities, may be substantially dependent upon whether the Company can obtain sufficient funding on terms acceptable to the Company. Proceeds from additional capital transactions would allow the Company to accelerate and/or expand its planned research and development activities. In the event that sufficient funds were not available, the Company may be required to delay or reduce expenditures to conserve cash, which could involve scaling back or curtailing development and general and administrative activities.</p> </div>
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-18571000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-34649000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-41699000
	us-gaap	Operating Expenses OperatingExpenses	43380000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	50108000
	us-gaap	Net Income Loss NetIncomeLoss	-41699000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-42465000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	766000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-28000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31603000
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-193000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	42000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	113012000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48674000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	94432000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-2000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	276000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	39000
	us-gaap	Sales Revenue Net SalesRevenueNet	915000
	us-gaap	Share Based Compensation ShareBasedCompensation	4170000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	0	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46577	shares
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	39000
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48675000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	276000
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	59000
	dei	Trading Symbol TradingSymbol	SNDX
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20004409	shares
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10426000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33585000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	328941000
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	-12000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.70
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1703000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10349000
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of costs and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. The Company’s actual results may differ from these estimates under different assumptions or conditions.</p> </div>
	sndx	Stock Issued During Period Value New Issues Under The At The Market Program StockIssuedDuringPeriodValueNewIssuesUnderTheAtTheMarketProgram	1083000
	sndx	Vesting Of Restricted Stock Value VestingOfRestrictedStockValue	59000
	sndx	Recent Accounting Standards Expected Date Of Adoption RecentAccountingStandardsExpectedDateOfAdoption	2018-01-01
	sndx	Proceeds From Issuance Of Common Stock In At Market Stock Offering Net ProceedsFromIssuanceOfCommonStockInAtMarketStockOfferingNet	1121000
	sndx	Number Of Revenue Arrangement NumberOfRevenueArrangement	1	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3761000
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-915000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	558000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3884000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	80000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	688000
	us-gaap	Interest Paid InterestPaid	2000
	us-gaap	Licenses Revenue LicensesRevenue	915000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-39711000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24741000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36255000
	us-gaap	Share Based Compensation ShareBasedCompensation	3761000
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	2598000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13419919	shares
	us-gaap	Operating Expenses OperatingExpenses	33540000
	sndx	Fair Value Adjustment Of Warrants And Derivative Liabilities FairValueAdjustmentOfWarrantsAndDerivativeLiabilities	-1720000
	sndx	Reclassification Of Common Stock Warrant Liability To Additional Paid In Capital ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital	4551000
	sndx	Issuance Costs Included In Accounts Payable And Accrued Expenses IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses	29000
	sndx	Vesting Of Restricted Stock Value VestingOfRestrictedStockValue	31000
CY2017Q2	sndx	Payment Specified Percentage Of Gross Proceeds From Sale Of Shares PaymentSpecifiedPercentageOfGrossProceedsFromSaleOfShares	0.03	pure
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3269000
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	268000
CY2016Q3	us-gaap	Licenses Revenue LicensesRevenue	305000
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14969000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	15543000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-14969000
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	792000
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15061000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	54026000
	us-gaap	Net Income Loss NetIncomeLoss	-33657000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32625000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1032000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	72000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261000
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	131752000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	92402000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-3000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	52177000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1852000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23191000
	us-gaap	Sales Revenue Net SalesRevenueNet	915000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15238000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	269000
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-92000
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12274000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	305000
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17899481	shares
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1346000
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15096000
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.68
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3563000
CY2017Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	411000
CY2017Q3	us-gaap	Licenses Revenue LicensesRevenue	305000
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15088000
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	15751000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-15088000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15446000
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	358000
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-8000
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-53000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12188000
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	305000
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22239996	shares

Files In Submission

Name	View Source	Status
0001193125-17-336444-index-headers.html	Edgar Link	pending
0001193125-17-336444-index.html	Edgar Link	pending
0001193125-17-336444.txt	Edgar Link	pending
0001193125-17-336444-xbrl.zip	Edgar Link	pending
d441588d10q.htm	Edgar Link	pending
d441588dex311.htm	Edgar Link	pending
d441588dex312.htm	Edgar Link	pending
d441588dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sndx-20170930.xml	Edgar Link	completed
sndx-20170930.xsd	Edgar Link	pending
sndx-20170930_cal.xml	Edgar Link	unprocessable
sndx-20170930_def.xml	Edgar Link	unprocessable
sndx-20170930_lab.xml	Edgar Link	unprocessable
sndx-20170930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNDX
Syndax Pharmaceuticals Inc Stock $sndx

2017 Q4 Form 10-Q Financial Statement

#000119312517336444 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNDX Syndax Pharmaceuticals Inc Stock $sndx

2017 Q4 Form 10-Q Financial Statement

#000119312517336444 Filed on November 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNDX
Syndax Pharmaceuticals Inc Stock $sndx